New Delhi, 8 May (IANS). India’s Pharmaceutical Market (IPM) continued to increase revenue by 7.8 percent in April this year. This information was given in a report on Thursday.
According to the report by the rating agency ‘India Ratings and Research’ (Ind-Ra), the growth has been recorded due to the price hike of companies, with an increase of 1.3 percent in the volume. Almost all major chronic therapy has also recorded positive values and volume growth.
Nishith Sanghvi, director of Ind-Ra corporate ratings, said, “Ind-Ra is expected to increase the IPM during FY 2026, with a continuous increase in chronic therapy. This will be seen with continuous increase in chronic therapy. This continuous increase will be seen with price increase and launch of new products.”
The report showed that the volume growth in April was 2.8 percent on an annual basis due to genericization opportunities in the anti-dibitic segment.
Volume growth of major therapy such as 5.5 percent in the Gastro-Intestinal, 3.1 percent in Derma and 2.2 percent in Cardiac.
In addition, there was a stable performance in April 2025, where the price increase in all therapy was observed.
Therapy such as cardiac, gastrointestinal, anti-dibitic and darma saw a greater increase in volume than IPM.
A sales growth of 10.1 percent, 7.5 percent, 8.5 percent and 6.5 percent, respectively, saw 10.1 percent, 7.5 percent, 8.5 percent and 6.5 percent sales growth respectively in gastro-interest, vitamins, pain/analgesic and anti-informative.
Chronic therapy such as Derma, Cardiac, Anti-Diabitic and CNS increased by 10.8 percent, 10.6 percent, 7.7 percent and 9.1 percent respectively.
The Ind-Ra march report showed that the sales of the acute segment increased by 6.4 percent on an annual basis.
Cardiac (13.4 percent chronic), anti-informative (11.7 percent acute), Gastro-Intestinal (12.1 percent acute), Anti-Diabitic (9.2 percent chronic) and vitamins (9.0 percent acute) contributed 55 percent in IPM in March 2025.
-IANS
SKT/Ekde
